First Trust Nasdaq Pharmaceuticals ETF(FTXH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
WEAK BUY
BUY for 124 days
PROFIT SINCE LAST BUY
+18.93% ▲
LAST CLOSE
$41.71
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FTXH

11/20/2026: FTXH (2-star) has a low Upturn Star Rating. Not recommended to BUY.

First Trust Nasdaq Pharmaceuticals ETF (FTXH) provides targeted exposure to large and liquid U.S. pharmaceutical companies through a rules-based smart-beta index that screens for value, growth, low volatility, and liquidity. Its main strengths lie in its systematic multi-factor methodology and liquidity-focused design, which help mitigate single-stock concentration risks. It serves primarily as a tactical sector allocation tool or a specialized core-satellite holding for healthcare exposure. Key risks include a relatively high expense ratio of 0.60% and industry-specific vulnerabilities such as drug pricing regulations and patent expirations. The fund is well-suited for growth- or value-conscious investors looking for systematic pharmaceutical exposure while monitoring regulatory and sector performance drivers.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitPharmaceutical sectors generally blend stable cash flows with moderate growth rather than aggressive expansion.
Momentum investorStrong fit while signal remains positiveThe index explicitly screens for positive price momentum factors during its quarterly evaluations.
Value investorStrong fitThe smart-beta design incorporates cash-flow-to-price metrics to tilt allocations toward attractive valuations.
Dividend/Income investorMixed fitWhile many pharma holdings pay dividends, FTXH prioritizes multi-factor scoring over high-yield optimization.
Low-risk investorMixed fitSector concentration introduces industry-specific regulatory and clinical trial risks despite low-volatility screening.

Investor Profile

Ideal Investor Profile

Investors seeking targeted, factor-screened exposure to the U.S. pharmaceutical industry who prefer a rules-based alternative to traditional market-cap weighting.

Suitability

Best suited for long-term strategic asset allocation or tactical sector rotation within a diversified investment portfolio.

Risk Profile

Risk factorLevelWhy it matters
VolatilityMediumHealthcare stocks offer defensive characteristics, though individual stock volatility is moderated via factor screening.
Market riskMedium / highBroader macroeconomic shocks and equity market drawdowns directly impact fund performance.
ConcentrationHighThe fund restricts exposure to a focused basket of approximately 30 to 50 pharmaceutical firms.
Tracking/expenseMediumAn expense ratio of 0.60% is somewhat elevated compared to broader health sector index funds.
LiquidityLowUnderlying holdings are selected for high daily trading volumes, supporting efficient creation and redemption.
Business/sector qualityMedium / highConstituents are established domestic pharmaceutical leaders with robust balance sheets and cash flows.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

Historical volatility is kept moderate due to the inclusion of low-volatility factor filters, though sector-specific shocks can induce short-term price swings.

Market Risk

Subject to systematic equity risks as well as regulatory, legal, and clinical trial outcomes unique to pharmaceutical companies.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
IndustryU.S. Pharmaceuticals & Biotechnology Equity Securities96Provides targeted multi-factor exposure to the domestic pharmaceutical industry.
Cash/collateralCash and Cash Equivalents4Maintains a minor liquidity buffer for daily administrative efficiency and operational distributions.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit 63.77%
Avg. Invested days 100
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 5.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.